Sugi Predict

Sugi Predict / Targets / BRPF3

BRPF3

Bromodomain and PHD finger-containing protein 3 · Q9ULD4 · BRPF3 on Sugi Atlas →

4,652 patent compounds predicted against BRPF3, 3,416 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8016504 SCHEMBL8016504 0.48 7/20
SCHEMBL14722196 SCHEMBL14722196 0.71 6/20
SCHEMBL8029898 SCHEMBL8029898 0.60 6/20
SCHEMBL12050293 SCHEMBL12050293 0.60 6/20
SCHEMBL6658847 SCHEMBL6658847 0.60 6/20
SCHEMBL12050292 SCHEMBL12050292 0.59 6/20
SCHEMBL12050296 SCHEMBL12050296 0.56 6/20
SCHEMBL6637215 SCHEMBL6637215 0.52 6/20
SCHEMBL4193118 SCHEMBL4193118 0.46 6/20
SCHEMBL4192303 SCHEMBL4192303 0.46 6/20
SCHEMBL4193183 SCHEMBL4193183 0.46 6/20
SCHEMBL13742709 SCHEMBL13742709 0.64 5/20
SCHEMBL7981348 SCHEMBL7981348 0.56 5/20
SCHEMBL1319712 SCHEMBL1319712 0.49 5/20
SCHEMBL10034994 SCHEMBL10034994 0.46 5/20
SCHEMBL1948671 SCHEMBL1948671 0.38 5/20
SCHEMBL10909054 SCHEMBL10909054 0.38 5/20
SCHEMBL4198329 SCHEMBL4198329 0.37 5/20
SCHEMBL1450538 SCHEMBL1450538 0.34 5/20
SCHEMBL8032270 SCHEMBL8032270 0.54 4/20

Clinical trials — most relevant to BRPF3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients PHASE1UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Chilean Gastric Cancer Task Force (FORCE 1) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BRPF3 binder may also engage these)

ProteinNameSimilarity
B2RRD7 — 1.000 B2RRD7 →
B2KF05 — 1.000 B2KF05 →
Q9H329 — 0.997 Q9H329 →
Q9NRR4 — 0.995 Q9NRR4 →
Q8BMD7 — 0.995 Q8BMD7 →
BRPF1 Peregrin 0.995 landscape →
KDM2B Lysine-specific demethylase 2B 0.995 landscape →
BRD1 Bromodomain-containing protein 1 0.994 landscape →
Q08BS4 — 0.994 Q08BS4 →
A0A286Y9D1 — 0.994 A0A286Y9D1 →
Q9P2R6 — 0.994 Q9P2R6 →
Q80TM9 — 0.994 Q80TM9 →
Q96PX1 — 0.993 Q96PX1 →
Q5TKR9 — 0.993 Q5TKR9 →
Q99P99 — 0.992 Q99P99 →
Q5VW22 — 0.992 Q5VW22 →
KAT6A Histone acetyltransferase KAT6A 0.992 landscape →
Q6IVY4 — 0.992 Q6IVY4 →
Q8VDU5 — 0.992 Q8VDU5 →
Q5RAK6 — 0.992 Q5RAK6 →
Q4R381 — 0.992 Q4R381 →
G5EEM9 — 0.991 G5EEM9 →
Q7TMI3 — 0.991 Q7TMI3 →
Q9ERE6 — 0.991 Q9ERE6 →
Q9NJG9 — 0.991 Q9NJG9 →
Q5R8Z4 — 0.991 Q5R8Z4 →
Q8BGT6 — 0.991 Q8BGT6 →
Q12756 — 0.991 Q12756 →
Q8WML3 — 0.991 Q8WML3 →
Q13415 — 0.991 Q13415 →